Rethinking risk indices in pediatric MASLD.
作者信息
Li Sheng, Mao Qianqian
机构信息
Department of Anorectal Surgery, Ningbo No.2 Hospital, Ningbo, Zhejiang, China.
Department of General Surgery, Cixi Maternity and Child Health Care Hospital, Ningbo, Zhejiang, China.
出版信息
JHEP Rep. 2025 Jul 12;7(10):101522. doi: 10.1016/j.jhepr.2025.101522. eCollection 2025 Oct.
Abstract
摘要
相似文献
1
Rethinking risk indices in pediatric MASLD.重新审视儿童非酒精性脂肪性肝病的风险指数。
JHEP Rep. 2025 Jul 12;7(10):101522. doi: 10.1016/j.jhepr.2025.101522. eCollection 2025 Oct.
2
Reply to: "Rethinking risk indices in pediatric MASLD".回复：“重新思考儿童非酒精性脂肪性肝病的风险指数”。
JHEP Rep. 2025 Jul 31;7(10):101533. doi: 10.1016/j.jhepr.2025.101533. eCollection 2025 Oct.
3
Optimal Cutoffs of Fatty Liver Index and Hepatic Steatosis Index in Diagnosing Pediatric Metabolic Dysfunction-associated Steatotic Liver Disease.用于诊断儿童代谢功能障碍相关脂肪性肝病的脂肪肝指数和肝脂肪变性指数的最佳临界值
Clin Gastroenterol Hepatol. 2025 Jun 27. doi: 10.1016/j.cgh.2025.06.011.
4
Call to action - pediatric MASLD requires immediate attention to curb health crisis.行动呼吁——儿童非酒精性脂肪性肝病相关代谢功能障碍需要立即引起关注，以遏制健康危机。
Hepatology. 2025 Jun 23. doi: 10.1097/HEP.0000000000001440.
5
Associations Between Shift Work, Sociodemographic and Lifestyle Characteristics, Body Measurements, and MASLD.轮班工作、社会人口学和生活方式特征、身体测量指标与代谢功能障碍相关脂肪性肝病之间的关联。
Life (Basel). 2025 Jun 16;15(6):961. doi: 10.3390/life15060961.
6
Metabolic dysfunction-associated steatotic liver disease is associated with the risk of severe liver fibrosis in pediatric population.代谢功能障碍相关脂肪性肝病与儿童人群严重肝纤维化风险相关。
Gastroenterol Rep (Oxf). 2025 Jun 16;13:goaf056. doi: 10.1093/gastro/goaf056. eCollection 2025.
7
Anthropometric Measures and Mortality Risk in Individuals With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A Population-Based Cohort Study.代谢功能障碍相关脂肪性肝病（MASLD）患者的人体测量指标与死亡风险：一项基于人群的队列研究
Aliment Pharmacol Ther. 2025 Jul;62(2):168-179. doi: 10.1111/apt.70174. Epub 2025 May 14.
8
Beyond BMI: revealing metabolic risk in lean MASLD.超越体重指数：揭示瘦型代谢相关脂肪性肝病的代谢风险。
Arch Clin Cases. 2025 Aug 4;12(3):110-118. doi: 10.22551/2025.48.1203.10322. eCollection 2025.
9
Glucagon-like Peptide-1 Receptor Agonists-A Potential New Medication for Pediatric Metabolic-Dysfunction-Associated Steatotic Liver Disease (MASLD).胰高血糖素样肽-1受体激动剂——治疗儿童代谢功能障碍相关脂肪性肝病（MASLD）的一种潜在新药。
Children (Basel). 2024 Feb 23;11(3):275. doi: 10.3390/children11030275.
10
Identification of pediatric MASLD using insulin resistance indices.使用胰岛素抵抗指数识别儿童代谢相关脂肪性肝病
JHEP Rep. 2025 Apr 3;7(7):101419. doi: 10.1016/j.jhepr.2025.101419. eCollection 2025 Jul.
本文引用的文献
1
Identification of pediatric MASLD using insulin resistance indices.使用胰岛素抵抗指数识别儿童代谢相关脂肪性肝病
JHEP Rep. 2025 Apr 3;7(7):101419. doi: 10.1016/j.jhepr.2025.101419. eCollection 2025 Jul.
2
Prevalence and Predictors of Suspected Metabolic Dysfunction-Associated Steatotic Liver Disease in Adolescents in the United States.美国青少年疑似代谢功能障碍相关脂肪性肝病的患病率及预测因素
Aliment Pharmacol Ther. 2025 May;61(9):1479-1488. doi: 10.1111/apt.70022. Epub 2025 Feb 12.
3
Prevalence of steatotic liver disease (MASLD, MetALD, ALD) and clinically significant fibrosis in US adolescents : Authors' name.美国青少年脂肪性肝病（MASLD、MetALD、ALD）和临床显著纤维化的流行情况：作者姓名。
Sci Rep. 2024 Oct 28;14(1):25724. doi: 10.1038/s41598-024-76922-9.
4
Magnetic Resonance Imaging-Proton Density Fat Fraction vs. Transient Elastography-Controlled Attenuation Parameter in Diagnosing Non-alcoholic Fatty Liver Disease in Children and Adolescents: A Meta-Analysis of Diagnostic Accuracy.磁共振成像-质子密度脂肪分数与瞬时弹性成像-受控衰减参数在诊断儿童和青少年非酒精性脂肪性肝病中的比较：诊断准确性的Meta分析
Front Pediatr. 2022 Jan 11;9:784221. doi: 10.3389/fped.2021.784221. eCollection 2021.
5
A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement.代谢相关脂肪性肝病新定义：国际专家共识声明。
J Hepatol. 2020 Jul;73(1):202-209. doi: 10.1016/j.jhep.2020.03.039. Epub 2020 Apr 8.
Zotero 插件